On July 8, 2016, the federal Department of Health and Human Services released this final rule regarding treatment for opioid use disorders. This final rule increases access to medication-assisted treatment with buprenorphine and the combination buprenorphine/naloxone in the office-based setting as authorized under the United States Code. This final rule is effective on August 8, 2016 . . .